The investigation is divided into two parts to first determine the most appropriate amount of the medicine to give and then to see how well it works. The medication is administered as a subcutaneous injection, which is a type of injection given into the fatty tissue just under the skin. Participants will receive the treatment for a series of cycles to monitor how the disease responds over time.

The purpose of the study is to find out whether treatment with zanubrutinib for twelve months can lead to improvement in nerve function as measured by various scales that assess strength, sensation, and ability to perform daily activities. These scales help doctors understand how well patients can move, feel sensations, and carry out everyday tasks. The study will measure whether patients improve by at least one point on at least two of these measurement scales after one year of treatment.

During the study, patients will take zanubrutinib capsules daily for up to forty-eight months. The maximum daily amount is three hundred twenty milligrams, and the maximum total amount in a day is four hundred eighty milligrams. Doctors will regularly check nerve function using the measurement scales and will also perform nerve conduction studies, which are tests that measure how well electrical signals travel through the nerves. Blood tests will be done to measure the levels of abnormal proteins and anti-MAG antibodies at twelve, twenty-four, and forty-eight months to see if the treatment is reducing these harmful substances in the blood.

The study includes different groups of patients: those whose disease has returned or not responded to previous treatments (relapsed/refractory disease), those who couldn’t tolerate certain previous treatments, and those who haven’t received any treatment yet for their Waldenström Macroglobulinemia. During the study, participants will receive either sonrotoclax alone or in combination with zanubrutinib, depending on which study group they join.

Researchers will track how well patients respond to the treatment by measuring changes in their cancer. They will also monitor side effects, laboratory test results, and how the treatment affects patients’ quality of life and symptoms related to their disease.

Participants in this study will continue taking ibrutinib in the form of a hard capsule, which is taken orally. The study will monitor the long-term effects of ibrutinib and any potential side effects that may arise. Patients will be observed for any serious adverse events, which are significant health issues that may occur during the treatment. The study aims to ensure that patients who benefit from ibrutinib can maintain their treatment regimen and continue to manage their condition effectively.

The purpose of the study is to determine how well the combination of Venetoclax and Rituximab works compared to the other treatment option in patients who have not been treated for Waldenström’s Macroglobulinemia before. Participants in the study will receive either the Venetoclax and Rituximab combination or the Dexamethasone, Rituximab, and Cyclophosphamide combination. The study will last for several months, during which time participants will receive their assigned treatment and be monitored for their response to the therapy.

Throughout the study, researchers will assess the participants’ health and the effectiveness of the treatments. The main focus will be on the rate of complete or very good partial remission, which means the cancer has significantly decreased or disappeared. The study will also look at other outcomes, such as the time it takes for the treatment to start working, how long the response lasts, and the overall survival of the participants. Safety and quality of life will also be important considerations during the trial.

The purpose of this study is to evaluate how well CLR 131 works in patients who have already tried at least two other treatments for their condition. Participants in the study will receive the treatment and be monitored over a period of time to see how their cancer responds. The study will look at various outcomes, such as how many patients experience a significant reduction in their cancer, how long they remain free from needing further treatment, and the overall safety of the treatment.

Throughout the study, patients will undergo regular assessments to track their response to the treatment and any side effects they may experience. These assessments will include checking vital signs, performing laboratory tests, and possibly conducting electrocardiograms (ECGs) to monitor heart health. The study aims to provide valuable information on the effectiveness and safety of CLR 131 for patients with Waldenstrom Macroglobulinemia and other B-Cell malignancies.

Participants in the study will receive the treatment through an intravenous infusion, which means it is given directly into the bloodstream. The study will also involve other medications, including ibrutinib, a drug that helps block certain proteins that cancer cells need to grow, and cyclophosphamide, a type of chemotherapy. Additionally, supportive medications like mesna to protect the bladder, methylprednisolone and dexamethasone as corticosteroids to reduce inflammation, and fludarabine, another chemotherapy drug, may be used. Some participants may receive a placebo instead of certain medications to compare the effects.

The study will take place over several months, with regular check-ups to monitor the participants’ health and the effectiveness of the treatment. The goal is to see how well the treatment works in reducing the cancer and improving the patients’ condition. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of this study is to gather information on the long-term safety of venetoclax for patients who have completed a previous trial involving this medication. Participants will continue to receive venetoclax, and their health will be monitored over time to collect data on any adverse events, which are any unwanted effects that may occur during the treatment. The study will involve taking venetoclax in the form of tablets, which are either dispersible or film-coated, and are taken orally.

Throughout the study, participants will be required to follow specific procedures and guidelines, especially those with Multiple Myeloma, who will need to take preventive antibiotics to reduce the risk of infections. The study is expected to continue until early 2026, allowing researchers to collect comprehensive safety data over an extended period. Participants will not be directly addressed or encouraged to join the study, as the information provided is purely informational.

The purpose of the study is to explore how well the combination of Carfilzomib and Ibrutinib works compared to Ibrutinib alone in patients who are either newly diagnosed or have had a return of the disease after previous treatment. Participants will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period to see how their disease responds to the treatment and to check for any side effects.

Throughout the study, researchers will look at various outcomes, such as how long it takes for the disease to respond to treatment, how long the response lasts, and the overall survival of the participants. The study will also assess the quality of life of the participants during the treatment period. This trial aims to provide valuable information on the potential benefits of adding Carfilzomib to the treatment plan for patients with Waldenström’s Macroglobulinemia.

The purpose of the study is to evaluate how effective this combination is in preventing the progression of the disease over a one-year period. Participants in the study will receive the treatment and be monitored for changes in their condition. The study will track how long it takes for the disease to respond to the treatment and how long the response lasts. The safety of the treatment and any side effects will also be closely observed.

Participants will receive Bortezomib as a solution for injection, Rituximab either as an infusion or injection, and Ibrutinib in capsule form. The study will follow a specific schedule for administering these medications and will include regular check-ups to assess the participants’ health and the treatment’s impact on their condition. The study aims to provide valuable information on the potential benefits of this treatment combination for patients with Waldenström’s Macroglobulinemia.